Who are Pyrimethamine plus Sulfadiazine plus leucoverin's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Ivermectin 0.1% Metronidazole 1%, Pyrimethamine/Sulfadiazine.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/pyrimethamine-plus-sulfadiazine-plus-leucoverin.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-18 · How we verify

Pyrimethamine plus Sulfadiazine plus leucoverin — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Pyrimethamine plus Sulfadiazine plus leucoverin (Pyrimethamine plus Sulfadiazine plus leucoverin) competitive landscape: 2 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antiparasitic/antimicrobial combination. Area: Infectious Disease.

marketed Antiparasitic/antimicrobial combination Dihydrofolate reductase (parasitic and bacterial) Infectious Disease Small molecule Live · refreshed every 30 min

Target snapshot

Pyrimethamine plus Sulfadiazine plus leucoverin (Pyrimethamine plus Sulfadiazine plus leucoverin) — Department of Medical Services Ministry of Public Health of Thailand. This combination inhibits parasitic dihydrofolate reductase to block nucleotide synthesis, with sulfadiazine providing synergistic antimicrobial activity and leucovorin protecting host cells from folate antagonism.

Comparator set (2 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Pyrimethamine plus Sulfadiazine plus leucoverin TARGET	Pyrimethamine plus Sulfadiazine plus leucoverin	Department of Medical Services Ministry of Public Health of Thailand	marketed	Antiparasitic/antimicrobial combination	Dihydrofolate reductase (parasitic and bacterial)
Ivermectin 0.1% Metronidazole 1%	Ivermectin 0.1% Metronidazole 1%	Universidad Nacional de Colombia	phase 3	Antiparasitic/Antimicrobial combination	Glutamate-gated chloride channels (ivermectin); DNA/anaerobic metabolism (metronidazole)
Pyrimethamine/Sulfadiazine	Pyrimethamine/Sulfadiazine	Assistance Publique - Hôpitaux de Paris	phase 3	Antiparasitic/Antimicrobial combination	Dihydrofolate reductase (pyrimethamine); Dihydropteroate synthase (sulfadiazine)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antiparasitic/antimicrobial combination class)

Department of Medical Services Ministry of Public Health of Thailand · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Pyrimethamine plus Sulfadiazine plus leucoverin — Competitive Intelligence Brief. https://druglandscape.com/ci/pyrimethamine-plus-sulfadiazine-plus-leucoverin. Accessed 2026-05-18.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab